Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798208 | 0.85 | HTT (0.59) | L3MBTL1POLBSMN1; SMN2GLAKDM4E | |
| SCHEMBL3409855 | 0.83 | L3MBTL1 (0.67) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL266662 | 0.83 | L3MBTL1 (0.72) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL503961 | 0.83 | L3MBTL1 (0.77) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL7402587 | 0.83 | KDM4E (0.61) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL29682135 | 0.82 | L3MBTL1 (0.80) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL340762 | 0.82 | L3MBTL1 (0.80) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL4300659 | 0.81 | L3MBTL1 (0.65) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL4837994 | 0.81 | L3MBTL1 (0.65) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL11204805 | 0.81 | L3MBTL1 (0.65) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008144604-A1 | SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080287505-A1 | SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-11-20 | — | — | US | disclosed |
| US-6010826-A | Resist composition | NIPPON ZEON CO., LTD. (JP) | 2000-01-04 | — | — | US | disclosed |
| EP-0786701-A1 | RESIST COMPOSITION | NIPPON ZEON CO., LTD. (JP) | 1997-07-30 | — | — | EP | disclosed |
| US-5545568-A | ARRAY OF COMPOUNDS ON SUBSTRATE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-08-13 | — | — | US | disclosed |
| US-4668698-A | [(4-phenyl-1,3-dioxan-cis-5-yl)alkyl]phenylalkanoic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287505-A1 | SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | L3MBTL1 3370/4885POLB 3369/4885SMN1; SMN2 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.